Boston, MA, United States of America

Lionel Apetoh

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Lionel Apetoh

Introduction

Lionel Apetoh is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work focuses on understanding the mechanisms of cancer resistance and developing methods to improve treatment outcomes.

Latest Patents

Lionel Apetoh holds a patent titled "Toll like receptor 4 dysfunction and the biological applications thereof." This invention relates to an in vitro method for assessing a subject's sensitivity to cancer treatment. The method involves detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or abnormal TLR4 protein expression or activity in a sample from the subject. The presence of these mutations indicates resistance to treatment. Additionally, the invention provides compounds for treating or preventing cancer in subjects with these specific TLR4 abnormalities. He has 1 patent to his name.

Career Highlights

Apetoh's career is marked by his dedication to cancer research and his role at the Institut Gustave Roussy. His work has contributed to a deeper understanding of cancer biology and the development of targeted therapies. His innovative approach has garnered attention in the scientific community.

Collaborations

Lionel Apetoh has collaborated with notable researchers in the field, including Guido Kroemer and Laurence Zitvogel. These collaborations have further enhanced the impact of his research and contributed to advancements in cancer treatment.

Conclusion

Lionel Apetoh's contributions to cancer research through his innovative patent and collaborations highlight his commitment to improving treatment outcomes for patients. His work continues to inspire advancements in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…